# Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

> **NCT00017680** · PHASE2 · COMPLETED · sponsor: **Herbert Irving Comprehensive Cancer Center** · enrollment: 25 (—)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Melphalan
- **PROCEDURE:** Autologous Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT00017680
- **Lead sponsor:** Herbert Irving Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 25 (—)
- **Last updated:** 2008-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017680, "Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00017680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*